Additional Information

Description

Stelara (ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), reducing inflammation and immune system overactivity. It is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in patients who have not responded adequately to other treatments. The intravenous formulation is specifically indicated for the induction phase of therapy in Crohn’s disease and ulcerative colitis before transitioning to subcutaneous maintenance dosing.

Patients receiving Stelara are at an increased risk of infections, including serious bacterial, fungal, and viral infections. Tuberculosis screening is required before initiating therapy, and patients must be monitored for signs of infection throughout treatment. Individuals with active infections should not start Stelara until their healthcare provider deems it safe.

Common side effects include headaches, fatigue, upper respiratory infections, nausea, and injection site reactions. Serious adverse effects may include severe infections, malignancies, and hypersensitivity reactions. Patients should report symptoms such as persistent fever, night sweats, unexplained weight loss, or difficulty breathing to their healthcare provider.